Literature DB >> 18587546

[Monoclonal antibodies. Principles, generation, application, and side effects].

U Sack1, F Emmrich.   

Abstract

The use of monoclonal antibodies for therapeutic purposes and diagnostic imaging has become an important pillar of internal medicine in recent years. Currently, the application of antibodies against cell surface receptors and cytokines makes specific therapies possible, in particular against chronic and malignant diseases. The production of antibody preparations increasingly involves gene and biotechnological processes while continuing to adhere to the basic principle of specific antigen-antibody binding. Despite the complex antigen structure of antibodies, severe treatment side effects remain the exception. This is all the more remarkable considering the increased use of human or humanized and functionally optimized antibodies. In the coming years, numerous new monoclonal antibodies will extend the therapeutic and diagnostic possibilities for diverse clinical applications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587546     DOI: 10.1007/s00108-008-2055-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  12 in total

1.  "Mutagenesis" by peptide aptamers identifies genetic network members and pathway connections.

Authors:  C R Geyer; A Colman-Lerner; R Brent
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 2.  Phage display of antibody fragments.

Authors:  A Pini; L Bracci
Journal:  Curr Protein Pept Sci       Date:  2000-09       Impact factor: 3.272

Review 3.  Human antibodies from transgenic animals.

Authors:  Nils Lonberg
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 4.  Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins".

Authors:  Steffen Schlehuber; Arne Skerra
Journal:  Drug Discov Today       Date:  2005-01-01       Impact factor: 7.851

5.  Screening for peptide drugs from the natural repertoire of biodiverse protein folds.

Authors:  Paul M Watt
Journal:  Nat Biotechnol       Date:  2006-02       Impact factor: 54.908

6.  Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core.

Authors:  Fabio Parmeggiani; Riccardo Pellarin; Anders Peter Larsen; Gautham Varadamsetty; Michael T Stumpp; Oliver Zerbe; Amedeo Caflisch; Andreas Plückthun
Journal:  J Mol Biol       Date:  2007-12-14       Impact factor: 5.469

7.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

Review 8.  HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab.

Authors:  Alan Kivitz; Oscar G Segurado
Journal:  Expert Rev Med Devices       Date:  2007-03       Impact factor: 3.166

Review 9.  The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis.

Authors:  Johan Askling; Will Dixon
Journal:  Curr Opin Rheumatol       Date:  2008-03       Impact factor: 5.006

Review 10.  Nanobodies in therapeutic applications.

Authors:  Rob C Roovers; Guus A M S van Dongen; Paul M P van Bergen en Henegouwen
Journal:  Curr Opin Mol Ther       Date:  2007-08
View more
  2 in total

1.  [Biologics. Magic bullets - magic effects - magic costs? New therapeutics and their effects].

Authors:  O Frey; T Kamradt
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

2.  Membrane Adsorber for the Fast Purification of a Monoclonal Antibody Using Protein A Chromatography.

Authors:  Chantal Brämer; Lisa Tünnermann; Alina Gonzalez Salcedo; Oscar-Werner Reif; Dörte Solle; Thomas Scheper; Sascha Beutel
Journal:  Membranes (Basel)       Date:  2019-11-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.